Two years of SARS-CoV-2 infection (2019–2021): structural biology, vaccination, and current global situation

Ahmad, Waqar; Shabbiri, Khadija

doi:10.1186/s43162-021-00092-7

The Egyptian Journal of Internal Medicine

Table 2 Details of vaccines against SARS-CoV-2 currently available or in clinical phase 3

From: Two years of SARS-CoV-2 infection (2019–2021): structural biology, vaccination, and current global situation

No.	Platform	Type	Doses	Dose schedule	Route	Developers
1	Inactivated virus	SARS-CoV-2 vaccine (inactivated)	2	Day 0 + 14	IM	Sinovac Research and Development Co., Ltd
2	Inactivated virus	Inactivated SARS-CoV-2 vaccine (Vero cell)	2	Day 0 + 21	IM	Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products
3	Inactivated virus	Inactivated SARS-CoV-2 vaccine (Vero cell)	2	Day 0 + 21	IM	Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products
4	Viral vector (non-replicating)	ChAdOx1-S—(AZD1222) (Covishield)	1–2	Day 0 + 28	IM	AstraZeneca + University of Oxford
5	Viral vector (non-replicating)	Recombinant novel coronavirus vaccine (adenovirus type 5 vector)	1	Day 0	IM	CanSino Biological Inc./Beijing Institute of Biotechnology
6	Viral vector (non-replicating)	Gam-COVID-Vac adeno-based (rAd26-S+rAd5-S)	2	Day 0 + 21	IM	Gamaleya Research Institute ; Health Ministry of the Russian Federation
7	Viral vector (non-replicating)	Ad26.COV2.S	1-2	Day 0 or Day 0 +56	IM	Janssen Pharmaceutical
8	Protein subunit	SARS-CoV-2 rS/Matrix M1-adjuvant (full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M)	2	Day 0 + 21	IM	Novavax
9	RNA-based vaccine	mRNA-1273	2	Day 0 + 28	IM	Moderna + National Institute of Allergy and Infectious Diseases (NIAID)
10	RNA -based vaccine	BNT162 (3 LNP-mRNAs )	2	Day 0 + 21	IM	Pfizer/BioNTech + Fosun Pharma
11	Protein subunit	Recombinant SARS-CoV-2 vaccine (CHO cell)	2-3	Day 0 + 28 or Day 0 + 28 + 56	IM	Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences
12	RNA-based vaccine	CVNCOV vaccine	2	Day 0 + 28	IM	CureVac AG
13	Inactivated virus	SARS-CoV-2 vaccine (vero cells)	2	Day 0 + 28	IM	Institute of Medical Biology + Chinese Academy of Medical Sciences
14	Inactivated virus	QazCovid-in®—COVID-19 inactivated vaccine	2	Day 0 + 21	IM	Research Institute for Biological 15Safety Problems, Rep of Kazakhstan
15	DNA-based vaccine	INO-4800 + electroporation	2	Day 0 + 28	ID	Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd
16	DNA-based vaccine	AG0301-COVID19	2	Day 0 + 14	IM	AnGes + Takara Bio + Osaka University
17	DNA-based vaccine	nCov vaccine	3	Day 0 + 28 + 56	ID	Zydus Cadila
18	DNA-based vaccine	GX-19	2	Day 0 + 28	IM	Genexine Consortium
19	Inactivated virus	Whole-virion inactivated SARS-CoV-2 vaccine (BBV152)	2	Day 0 + 14	IM	Bharat Biotech International Limited
20	Protein subunit	SCB-2019 + AS03 or CpG 1018 adjuvant plus alum adjuvant (native like trimeric subunit spike protein vaccine)	2	Day 0 + 21	IM	Clover Biopharmaceuticals Inc./GSK/Dynavax
21	Protein subunit	UB-612 (Multitope peptide based S1-RBD-protein based vaccine)	2	Day 0+28	IM	COVAXX + United Biomedical Inc
22	Virus-like particle	Coronavirus-like particle COVID-19 (CoVLP)	2	Day 0 + 21	IM	Medicago Inc.

Back to article page